Indoco Remedies has signed a definitive agreement to acquire Piramal Clinical Research (PCL), a Hyderabad-based Clinical Research Division (CRO) of Piramal Enterprises, on a going concern basis.

The CRO specializes in conducting bioequivalence and bioanalytical studies for generic products. This facility is spread across an area of 30,000 square feet and is equipped with a 98-bed facility, monitoring stations, phlebotomy stations, four-bed ICU, state-of-the-art analytical lab and capabilities of eCTD submission.

"We are extremely happy to have the CRO division of Piramals as part of Indoco. This acquisition will expand the depth of our services to customers in India as well as across the globe and would reduce our dependability to outsource bio-equivalence studies. Apart from reducing cost and ensuring time-bound outcome of studies, the CRO would be a perfect fit to our existing R&D efforts, including facilitation of ANDA/Dossier filings", said Ms Aditi Kare Panandikar, managing director, Indoco Remedies.